Back to top

Regeneron announces FDA, EMA accept cemdisiran submissions for review

Regeneron (REGN) announced that both the FDA and European Medicines Agency, or EMA, have accepted the regulatory applications for cemdisiran to tre...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Regeneron Pharmaceuticals, Inc. (REGN)